Tag : hemophilia

Latest News

Providing personalized care for bleeding disorders

Newsemia
An interview with Dr. Carmen Escuriola-Ettingshausen MD, Mörfelden-Walldorf, Germany on providing personalized care for bleeding disorders. Source link...
Pharma / Biotech

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.

Newsemia
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med. 2020 09 10;383(11):1018-1027 Authors: Konkle BA, Shapiro AD, Quon DV,...
Pharma / Biotech

Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.

Newsemia
Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. Thromb Haemost. 2020 Jul 29;: Authors: Garcia-Martínez...
Latest News

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

Newsemia
Bullement, A; McMordie, ST; Hatswell, AJ; Li, N; Wilson, K; (2020) Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe...
Pharma / Biotech

Bleeds and imaging scoring scales in relation to pharmacokinetics of coagulation factor VIII in Chinese pediatric patients with severe hemophilia A.

Newsemia
Related Articles Bleeds and imaging scoring scales in relation to pharmacokinetics of coagulation factor VIII in Chinese pediatric patients with severe hemophilia A. Thromb Res....
Pharma / Biotech

Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.

Newsemia
Related Articles Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost....
Latest News

Global Hemophilia Treatment Drugs Market Drivers, Restraints & Opportunities During the Forecast Period, 2018-2026 – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Hemophilia Treatment Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026” report has been added to ResearchAndMarkets.com’s offering. Hemophilia...
Pharma / Biotech

Pharmacokinetics, immunogenicity, safety and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).

Newsemia
Related Articles Pharmacokinetics, immunogenicity, safety and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). J Thromb...
Latest News

Genentech Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits for People With Hemophilia A at the ISTH 2019 Congress

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data for Hemlibra® (emicizumab-kxwh) across multiple...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World